Skip to main content
Log in

Treatment of Nonproliferative Diabetic Retinopathy with a Peptide Fraction from Bovine Factor VIII

A Multicentre Controlled Trial

  • Original Research Article
  • Published:
Drug Investigation Aims and scope Submit manuscript

Summary

28 patients with diabetic retinopathy randomly received oral treatment with a bovine factor VIII peptide fraction (Vueffe®) 0.5mg twice daily or calcium-dobesilate (Doxium®) 500mg twice daily for 4 months. Changes in the activity of plasma factor VIII fractions [von Willebrand factor (vWf); factor VIII-related antigen (FVIII:Ag); and factor VIII procoagulant activity (FVIII:C)] were determined during treatment, and compared at baseline with a control group of 10 diabetic patients without retinopathy. Bovine factor VIII peptide fraction reduced the high levels of vWf and FVII:Ag to values found in control patients without retinopathy, while no effect on FVIII:C was detected. Bovine factor VIII peptide fraction produced a statistically significantly greater reduction in vWf and FVIII:Ag than calcium-dobesilate: the percentage reduction of vWf was 33 vs 11 (p < 0.01), that of FVIII:Ag was 25 vs 7 (p < 0.01). In addition, the retinopathy improvement rate was 47% for bovine factor VIII peptide fraction and 8% for calcium-dobesilate (p = 0.037). It is concluded that bovine factor VIII peptide fraction improves diabetic retinopathy by lessening endothelial damage to retinal microvessels by reducing plasma vWf and FVIII:Ag activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Ammannati P, Siravo D, Azzarelli L, Chimenti M, Salvetti O, et al. Decrease of diffusion of glycosylated albumin in retinal microcirculation by peptide fraction from bovine factor VIII. Arzneimittel-Forschung 39: 661–664, 1989

    PubMed  CAS  Google Scholar 

  • Baldacci M, Catalani R, Fascetti E, Gervasi GR. Polypeptide fraction from bovine factor VIII does not influence platelet aggregation and blood coagulation. Pharmacological Research Communications 20: 7–12, 1988

    Article  PubMed  CAS  Google Scholar 

  • Colmann RW, Hirsh J, Marder VJ, Salzmann EW. Retinal microangiopathy, haemostasis and thrombosis: basic principles and clinical practice. Lippincott, Philadelphia, 1987

    Google Scholar 

  • Denson KWE. Factor VIII procoagulant activity: method of determination. In Biggs (Ed.) Human coagulation, haemostasis and thrombosis, p. 278, Blackwell Scientific Publishers, Oxford, 1972

    Google Scholar 

  • Foster PA, Fulcher CA, Houghten RA, Mahoney SG, Zimmerman TS. Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, two amino acid residues Threonine-Serine of the factor VIII heavy chain. Journal of Clinical Investigation 82: 123–128, 1988

    Article  PubMed  CAS  Google Scholar 

  • Gervasi GB, Bartoli C, Carpita G, Baldacci M. Decrease of bleeding time by a peptidic fraction from bovine factor VIII in laboratory animals. Arzneimittel-Forschung 38: 1268–1270, 1988

    PubMed  CAS  Google Scholar 

  • Jandie JH. Disorders of blood coagulation. In Jandle (Ed.) Blood: pathophysiology. Blackwell Scientific Publications, Oxford, 1991

    Google Scholar 

  • Martindale. James E.F. Reynolds (Ed.) The Extra Pharmacopea 29th ed., London, 1989

  • Morse PH. Diabetic oculopathy. In De Groot (Ed.) Endocrinology, Vol. 2, Saunders, Philadelphia, 1989

    Google Scholar 

  • Pandolfi M, Lars-Olaf A, Lars H. Increased von Willebrand antihaemophilic factor A in diabetic retinopathy. Acta Ophthalmologica 52: 823–828, 1974

    Article  PubMed  CAS  Google Scholar 

  • Raines G, Aumann H, Sykes S, Streat A. Multimeric analysis of von Willebrand factor by molecular sieving electrophoresis in sodium dodecyl sulphate agarose gel. Thrombosis Research 60: 201–212, 1990

    Article  PubMed  CAS  Google Scholar 

  • Sakariassen KS, Fressinaud E, Girma JP, Baumgartner HR, Meyer D. Mediation of platelet adhesion to fibrillar collagen in flowing blood by proteolytic fragment of human von Willebrand factor. Blood 67: 1515–1518, 1986

    PubMed  CAS  Google Scholar 

  • Tuddenham EGD, Lazarchick J, Hoyer LW. Synthesis and release of factor VIII by cultured human endothelial cells. British Journal of Haematology 47: 617–626, 1981

    Article  PubMed  CAS  Google Scholar 

  • Witte S. Coagulation factors and permeability process. Clinical Hemorheology 2: 561–577, 1982

    CAS  Google Scholar 

  • Witte S. Surface phenomena of coagulation factors in vivo, observed by fluorescence intravital microscopy. Annals of the New York Academy of Sciences 416: 426–438, 1983

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cardillo-Piccolino, F., Ghiglione, D., Santini, G. et al. Treatment of Nonproliferative Diabetic Retinopathy with a Peptide Fraction from Bovine Factor VIII. Drug Invest 4, 1–6 (1992). https://doi.org/10.1007/BF03258371

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03258371

Keywords

Navigation